Vildagliptin + Metformin
A fixed-dose combination of vildagliptin and metformin used for glycaemic control in adults with type 2 diabetes. Exact strengths, products and authorised uses depend on the country and product record.
At a glance
Combination snapshot
- Active ingredients
- Vildagliptin + metformin
- Drug classes
- DPP-4 inhibitor + biguanide
- Main established use
- Type 2 diabetes
- EU reference strengths
- 50/850 mg · 50/1000 mg
- Route
- Oral
- Evidence model
- Combination-specific where available
Active ingredients
Two medicines, one combination entity
The combination is a separate medicine entity, while each component remains independently addressable in the reference graph.
Vildagliptin
Increases incretin activity, supporting glucose-dependent insulin secretion and reducing glucagon release.
Metformin
Mainly reduces hepatic glucose production and improves insulin sensitivity.
View metformin profile →Established use
What is vildagliptin + metformin used for?
EU product information for vildagliptin/metformin fixed-dose products describes use, alongside diet and exercise, to improve glycaemic control in adults with type 2 diabetes in specified treatment situations. The exact authorised wording must be read from the product information for the user’s jurisdiction.
Mechanism
How the combination works
The two components act through different mechanisms; the combination is not simply a synonym for either ingredient alone.
| Component | Main role | Why it matters in the combination |
|---|---|---|
| Vildagliptin | DPP-4 inhibition | Supports glucose-dependent incretin effects. |
| Metformin | Reduces hepatic glucose production; improves insulin sensitivity | Provides the established biguanide component of treatment. |
Evidence by indication
Evidence is tracked for the combination itself
Where trials evaluate vildagliptin added to metformin or the fixed combination, that evidence belongs to this relationship rather than being inferred from metformin alone.
Glycaemic control in adults with type 2 diabetes
EMA’s Eucreas assessment states that studies of vildagliptin added to metformin supported use of the fixed-dose combination in the authorised treatment settings.
Formulations
Available strengths and formulations
Strengths are properties of marketed products, not of the abstract combination entity. The examples below are verified against current EU reference product information.
Other strengths or formulations should only appear after verification in a national regulatory record.
Marketed products
Products and brand names by country
The combination entity connects to country-specific product records. These are examples, not a claim that every product is available in every market.
Eucreas
Vildagliptin + metformin hydrochloride; EMA centrally authorised.
Vildagliptin / Metformin hydrochloride Accord
Contains the same active substances and references Eucreas in the EU authorisation pathway.
Safety context
Important considerations come from both components
Metformin-containing products require renal-function assessment and product-specific dose restrictions.
Vildagliptin product information includes hepatic precautions and monitoring requirements.
A rare but serious metformin-associated risk that shapes contraindications and interruption rules.
Risk depends on the wider regimen, particularly when other glucose-lowering medicines are used.
Regulatory layer
Regulatory status is stored at product and jurisdiction level
- EU reference medicine
- Eucreas
- EU ATC
- A10BD08
- Therapeutic area
- Type 2 diabetes mellitus
- Source status
- Current EMA product information checked
Connected reference
Explore the entities behind this combination
Sources & provenance
Primary sources
- European Medicines Agency — Eucreas EPARActive substances, authorised use, strengths, ATC and evidence summary.
- European Medicines Agency — Vildagliptin / Metformin hydrochloride AccordGeneric product relationship and active-substance confirmation.
This medicine reference is based on trusted medical and regulatory sources and is awaiting clinician review. It is not a substitute for personalized medical advice.